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Hepatitis C in the era of direct-acting
antivirals: real-world costs of untreated
chronic hepatitis C; a cross-sectional study
Jennifer Ann Kieran1,2*, Suzanne Norris3,7, Aisling O’Leary2,8, Cathal Walsh4, Raphael Merriman5, D. Houlihan5,
P. Aiden McCormick5, Susan McKiernan3,7, Colm Bergin6,7 and Michael Barry1,2
Abstract
Background: Recent advances in Hepatitis C therapeutics offer the possibility of cure but will be expensive. The
cost of treatment may be partially offset by the avoidance of advanced liver disease. We performed a micro-costing
study of the ambulatory healthcare utilisation of patients with Hepatitis C supplemented with inpatient diagnosis
related group costs.
Methods: The staff utilisation costs associated with a Hepatitis C ambulatory visit were measured and combined
with the costs of investigations to establish a mean cost per consultation. An annualised estimate of cost was
produced by multiplying this by the number of consultations accessed, stratified by degree of liver impairment.
Inpatient costs were established by identifying the number of inpatient episodes and multiplying by Irish diagnosis
related group costs. Non-parametric bootstrapping was performed to derive mean and 95%CI values.
Results: Two hundred and twenty-five patients were identified. The cost of an outpatient medical review was €136
(€3.60 SD). The cost of a Hepatitis C nursing review was €128 (€7.30 SD). The annual mean costs of care were as follows
(95%CI): Mild €398 (€336, €482), Moderate €417(€335, €503), Compensated cirrhosis €1790 (€990, €3164), Decompensated
cirrhosis €8302 (€3945, €14,637), Transplantation Year 1 €137,176 (€136,024, €138,306), Transplantation after Year 1 €5337
(€4942, €5799), Hepatocellular carcinoma €21,992 (€15,222, €29,467), Sustained virological response €44 (€16, €73).
Conclusions: The direct medical cost associated with Hepatitis C care in Ireland is substantial and increases exponentially
with progression of liver disease. The follow-up costs of patients with a sustained virological response in this cohort were
low in comparison to patients with chronic infection.
Keywords: Ireland, Health economics, Direct medical cost, Hepatitis C, Pharmacoeconomics
Background
Chronic Hepatitis C (HCV) is an important public
health challenge with the World Health Organisation
estimating that 185 million people are infected world-
wide [1]. There is an estimated 20,000 to 50,000 people
chronically infected with HCV in Ireland, the majority
of whom are yet to be diagnosed [2]. In its later stages,
HCV causes significant morbidity and mortality. Given
the clinical and economic burden caused by end-stage
liver disease from HCV, there is a drive in many health-
care systems to diagnose and treat people with HCV
before they develop clinical disease [3, 4]. After a decade
of little development in HCV therapy, there is presently a
rapidly expanding therapeutic armamentarium. Currently
licensed direct acting anti-virals (DAA’s) significantly
improve the treatment outcomes for patients with HCV
genotype 1 infection and further novel agents promise a
paradigm shift in the treatments and outcomes for pa-
tients with HCV of all genotypes [3, 5–10]. These novel
agents demonstrate excellent clinical efficacy but are more
costly than the previous standard of care, pegylated inter-
feron and ribavirin, which has been shown to have a
substantial budget impact in Ireland [11]. The budget
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impact of the DAA’s make their affordability challenging
in many healthcare systems, even when they are found to
be cost-effective. In order to accurately define the cost-
effectiveness of these agents in the Irish healthcare setting,
a research project was undertaken to define the direct
medical costs of HCV care in Ireland.
Methods
The majority of care provided for patients with HCV is
ambulatory in nature with inpatient care required in
some patients in the later stages of disease. A bottom-up
micro-costing project was undertaken at two large ter-
tiary referral hepatology services (Institution 1 and Insti-
tution 2) in Ireland to establish the cost of ambulatory
HCV care. In order to give a more complete picture of
the cost of HCV care, unit costs of hospital based proce-
dures and admissions were sourced from Irish Diagnosis
Related Group (DRG) costs and added to the ambulatory
care costs where appropriate. Over 4000 HCV patients
are registered for care between these Institutions, repre-
senting approximately half of the HCV patients cur-
rently diagnosed in Ireland [12]. The sample taken
encompasses patients along the full spectrum of HCV-
related liver disease and is representative of clinical care
in Ireland, which is funded and delivered through the
public health service. The cost of care associated with
HCV treatment was not included in this study.
Micro-costing of ambulatory care
In order to establish the staff utilisation involved in pro-
viding an outpatient HCV consultation, the time spent
by staff in providing consultations was measured. Ninety
patients had their medical consultation timed (51 pa-
tients from an unselected HCV cohort with all stages of
disease severity, 39 patients from the transplant service),
11 patients had their nursing consultation timed, 81 pa-
tients had their blood draw timed and 68 patients had
their administrative encounter timed. The unit cost asso-
ciated with this time was calculated using the mid-point
of the Health Service Executive (HSE) salary scales for
new-entrants in 2010 and adjusted for non-pay salary
cost as per guidelines [13–15].
Hospital electronic records were interrogated to estab-
lish the ordering frequency of a set of pertinent investi-
gations (Table 1) in a cohort of HCV patients for three
years between 2011 and 2013. Sixty-seven patient re-
cords were analysed (39 patients with chronic mild HCV
infection not undergoing HCV treatment and 28 pa-
tients with a sustained virological response (SVR)). The
unit costs applied to these investigations were obtained
from laboratory and radiology costs supplied by the fi-
nance departments at the participating hospitals and the
National Viral Reference Laboratory at University Col-
lege Dublin. The costs of these investigations were
divided by the number of outpatient visits attended by
the patient to derive a mean cost of investigations per
visit. The mean costs derived for staff and laboratory
utilisation were combined to develop an overall cost for
a HCV outpatient review.
In order to establish the number of clinical reviews
accessed by patients with HCV, a cohort of 225 patients
with HCV attending the two units was identified and
stratified into health-states according to clinical, radio-
logical and histological criteria. These are consistent
with the natural history of HCV. The health-states
established were: mild, moderate, compensated cirrhosis,
liver transplantation Year 1, liver transplantation after
Year 1, decompensated cirrhosis, hepatocellular carcin-
oma and sustained virological response (SVR). The hos-
pital electronic patient records (EPR) of the two units
were interrogated to establish how many annual consul-
tations by medical and nursing staff each patient
accessed from 2006 to 2012 and this was multiplied by
the cost of review established during the micro-costing
project. Consultations that took place over the course of
HCV treatment were excluded. Patient who had
achieved an SVR were assessed for the consultations
they accessed post successful treatment from 2011 to
2013 inclusive. This produced an annual cost of ambula-
tory care for patients with differing levels of HCV dis-
ease severity.
Number and cost of inpatient episodes for end-stage liver
disease
In addition to the ambulatory care costs, patients with
more severe forms of liver disease such as decompen-
sated cirrhosis, hepatocellular carcinoma and liver trans-
plantation have significant inpatient costs associated
with their care. A cohort of 13 patients with decompen-
sated cirrhosis and 27 patients with hepatocellular car-
cinoma was identified from the prospectively collected
clinical database of the Hepatology service of Institution
1. The number of inpatient and outpatient clinical epi-
sodes for the last three years of follow up or from diag-
nosis to death was established through interrogation of
the EPR. The HSE DRG cost of an inpatient admission
with liver disease from 2011 was applied to the inpatient
stays with outpatient costs applied as per the micro-
costing study. In addition, the duration of prescriptions
in months of high-cost drugs such as sorafenib and the
frequency of high-cost procedures such as Trans-arterial
chemo-embolisation (TACE) were established and in-
cluded in the cost estimates for HCC patients. The drug
cost of sorafenib was taken from the standard unit costs
from the High-tech Drug Scheme in Ireland, adjusted as
per guidelines from the National Centre for Pharmacoe-
conomics in Ireland [14].
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Cost of liver transplantation and post-transplantation care
The cost of liver transplantation in the first year post-
transplantation was established through a combination of
bottom-up micro-costing of the ambulatory care com-
ponent supplemented by the DRG cost of the in-
patient liver transplantation procedure. The cost of
the pre-transplantation work-up was determined by
micro-costing the pre-transplantation work-up proto-
col of Institution 2, which is the sole institution deliv-
ering liver transplantation services in the Republic of
Ireland. The number of outpatient consultations and
inpatient admissions required by 33 patients in the
immediate year post-transplantation and in 31 pa-
tients in the years thereafter was established from the
EPR of Institution 2 and the outpatient cost estab-
lished from the micro-costing study was applied to
outpatient consultations with the DRG cost of an
inpatient admission with liver disease in 2011 used
for the inpatient admission. The prescription of im-
munosuppressive therapies post-transplantation was
established from the prospectively collected trans-
plantation database in Institution 2 and the costs of
these prescriptions was calculated using standard unit
costs from the High-tech Drug Scheme in Ireland,
adjusted as per guidelines from the National Centre for
Pharmacoeconomics in Ireland [14]. The rate of valganci-
clovir prescription for post-transplantation prophylaxis was
estimated at 0.21 based on the rate of cytomegalovirus
seroprevalence in a cohort of Irish pregnant women [15].
These drug costs were added to the outpatient and in-
patient resources consumed to give a total cost for post-
transplantation care.
All costs had annual inflation of 4 % applied as per
guidance from the Irish Department of Finance. Table 1
Table 1 Health resource utilisation considered in derivation of cost of HCV Health-states
Input Mild Mod Comp.
Cirrhosis
Decomp.
Cirrhosis
HCC Transplant Year
1
Transplant > Year
1
SVR Source
OPD bundlea ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ Institution costs
FBC
Renal profile
Liver profile
Coagulation screen
AFP
HCV Viral load
Liver US
Staff Costs HSE salary scale
2010
Liver Biopsy ✓ ✓ ✓ HSE DRG 2011
OGDb ✓ ✓ ✓ HSE DRG 2011
Hepatology Medical review ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ Micro-costing
Hepatology Nursing review ✓ ✓ ✓ ✓ ✓ Micro-costing
Inpatient Admission ✓ ✓ ✓ ✓ ✓ HSE DRG 2011
Sorafenib ✓ Micro-costingd
TACEc ✓ Institution cost
Oncology/ Palliative OPD ✓ HSE DRG 2011
Dermatology OPD ✓ ✓ HSE DRG 2011
Hepatology Dayward
review
✓ ✓ HSE DRG 2011
Pre-transplant workup ✓ Micro-costing
3 months Prophylaxis ✓ Micro-costingd
Immunosuppression ✓ ✓ Micro-costingd
Diuretic/Beta-blocker ✓ ✓ Micro-costingd
Mod moderate, Comp. cirrhosis Compensated cirrhosis, Decomp. Cirrhosis decompensated cirrhosis, HCC hepatocellular carcinoma, Transplant Year 1 First
12 months of liver transplantation, Transplantation > Year 1 Transplantation After First 12 months, SVR Sustained Viral Response, HSE Health Service Executive,
DRG Diagnostic Related Group, PCRS Patient Care Reimbursement Service, OPD outpatient, aBundle: FBC Full Blood Count, Renal Profile Urea, Creatinine, Sodium,
Potassium, Bicarbonate; Liver Profile Albumin, Alanine amino transaminase, Aspartate amino transaminase, Gamma glutamyl transferase, Bilirubin, Lactate
Dehydrogenase; Coagulation Screen Prothrombin Time, Activated partial thromboplastin time, International Normalised Ratio, AFP Alpha fetoprotein, bOGD
Oesophago-gastro-duodenoscopy, cTACE Transarterial chemoembolisation, dUnit cost of drug sourced from the Primary Care Reimbursement System
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summarises the health resources evaluated and included
in each health-state and their source.
Statistical analysis
Descriptive statistics were performed on the results from
the micro-costing project to give average values with 95 %
Confidence Intervals (CI). Mean time required for clinical
review was examined for significant differences depending
on provider and clinical indication using an independent
t-test for those elements with two categories and a one-
way ANOVA for those with greater than two categories. A
p-value of less than 0.05 was considered significant. SPSS
V21 was used for this analysis.
Given the positive skew of the annual cost estimates for
the health-states, non-parametric bootstrapping was per-
formed to establish valid means. Mean and 95 % Confi-
dence intervals (95 % CI) are presented. The analysis was
performed using Microsoft Excel.
This study received approval from the Ethics Committee
of St James’s Hospital, Dublin and St Vincent’s University
Hospital, Dublin.
Results
Micro-costing of ambulatory care
Medical review
The average time spent per medical review was 17 min.
(95 % CI 15,19). Mean review times in both clinical sites
were the same. There was a significant difference in the
time required for a clinical consultation undertaken by a
doctor who had completed speciality training (consultant)
compared to one performed by a doctor-in-training (mean
time 13 versus 19 min p = 0.001) and in the time required
to review a patient depending on their indication for re-
view, as those with chronic HCV required more time.
Patients attending for a first review required an average of
16 min (95 % CI 13,19), those for routine HCV monitor-
ing required an average of 18 min (95 % CI 16, 20), while
those attending for review post-sustained viral response
required on average 8 min (95%CI 6,9) p = 0.03.
Nursing review
Clinical nurse specialist reviews of patients being assessed
for HCV treatment were timed. Those for pre-treatment
assessment or work-up required a mean of 20 min (95%CI
13,28).
Phlebotomy encounter
The average time required by phlebotomy staff for a
blood draw was 3.6 min (95%CI 3.0,4.2). There was no
difference in average times between sites.
Administration encounter
The average time taken by administrative staff to check
patients into and out of the outpatient clinic was 2.1 min
(95%CI 1.8,2.4). There was no difference in the time re-
quired between the two sites. An additional 14 min of
administrative time per patient was included to account
for the time required to source the patient medical re-
cords (4 min) and type the letter (10 min) to the patients’
general practitioner.
The overall cost of an outpatient HCV medical review
including staff utilisation (medical, administration, phlebot-
omy services) (€41) and laboratory/radiology tests (€95) was
estimated to be €136 (€3.60 SD).
The overall cost of a HCV clinical nurse specialist re-
view including staff utilisation (nursing, administration,
phlebotomy services) (€33) and laboratory/radiology inves-
tigations (€95) was estimated to be €128 (€7.30 SD).
Annual healthcare resource utilisation of patients with
hepatitis C
Two hundred and twenty-five patients were identified
and categorised by their degree of liver disease, repre-
senting 819 patient-years of follow-up. One hundred and
sixty-four (73 %) were male and the mean age of the
cohort was 46 years. Table 2 presents a summary of the
demographics and healthcare resource utilisation of these
patients established through interrogation of the EPR.
Seventeen percent of the evaluated cohort had mild
disease (n = 40). They accessed an average of 1.5 ambula-
tory care visits per year. Seventy percent (n = 28) had
undergone a liver biopsy. Twenty-nine patients (13 %)
had moderate disease and an average of 2.5 ambulatory
care episodes per annum. Eighteen patients (62 %) had
had a liver biopsy. Twenty-four patients (11 %) had com-
pensated cirrhosis, of whom fourteen had had a liver bi-
opsy performed (58 %) and sixteen had had upper GI
endoscopy (67 %). Nine patients with compensated cir-
rhosis required a liver-related inpatient hospital stay
(38 %) and one patient was admitted to the intensive
care unit on four occasions.
Six percent of the evaluated cohort (n = 13) had de-
compensated cirrhosis. Eleven (85 %) required inpatient
admissions. Four patients died over the course of the
follow-up (31 %). Three patients (23 %) required an In-
tensive care unit admission. Eleven patients (85 %)
underwent upper GI endoscopy; the majority (n = 7) had
one procedure (range 0–2).
Twelve percent of the cohort (n = 27) had HCC.
Twenty-two patients (81 %) required inpatient admis-
sions. Six patients (22 %) received treatment with sorafe-
nib for an average duration of four months (95%CI
3.1,5.5). Eighteen (67 %) had a trans-arterial chemo-
embolisation (TACE) procedure carried out. The major-
ity had this performed once (n = 10) however one patient
had 6 procedures (95 % CI 0.98, 1.4). Sixteen patients
died over the course of the follow-up (59 %) consistent
with the high mortality seen with this condition.
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Ten percent of the cohort (n = 28) had been treated
successfully for HCV. The cost of their follow-up care
was evaluated. Forty-six percent (n = 13) did not access
HCV review in the three years post-SVR. Five patients
(18 %) had cirrhosis. The mean number of annual med-
ical reviews was 0.36 (95CI 0.2, 0.5). The annual mean
cost of care post SVR was €44 (95 % CI €16, €73).
Healthcare resource utilisation of patients receiving liver
transplantation
The cost associated with the pre-transplant workup in-
cluding staff costs, laboratory and radiological investiga-
tions was €2828. The inputs considered as part of the
pre-transplant work-up are displayed in the Additional
file 1. The DRG cost of the liver transplantation proced-
ure in 2011 was €124,425. The mean number of out-
patient reviews in the first year post-transplant was 12
(95%CI 10.4,13.2) and four (95%CI 4.0,4.6) in the years
thereafter. The cost of an ambulatory care review includ-
ing monitoring of immunosuppression was €184.54
(€3.60 SD) Sixteen patients (48 %) required re-admission
under the liver service in the first year post-transplant.
The mean number of admissions was one (95%CI
0.6,1.6). Fifteen (48 %) patients required an inpatient stay
under the liver service in the years following their first
year post-transplant. Prednisolone was the most com-
monly prescribed immunosuppressive in the first year
post-transplant (88 %), followed by tacrolimus (81 %)
and mycophenolate mofetil (75 %). In subsequent years
the rate of prednisolone prescribing fell (33 %) and ta-
crolimus was the most commonly prescribed immuno-
suppressant (66 %). The cost of immunosuppressive
drugs was €3713 per person in the first year and
€3667 per person per year thereafter. The cost of
antimicrobial prophylaxis was €1081 in the first year
post-transplantation based on three months therapy
with co-trimoxazole and either valaciclovir (79 %) or
valganciclovir (21 %).
Direct medical cost of HCV care in Ireland
The direct medical costs of HCV care rose substantially
with progression of liver disease (Fig. 1). Patients with
mild liver disease accrued the least costs (€398) with pa-
tients in the first year post-transplantation accruing the
most cost (€137,176). Patients with non-cirrhotic disease
had significantly less cost than those with end-stage liver
disease (ESLD). Table 3 summarises the mean cost and
95 % confidence intervals of the different HCV health-
states.
Discussion
The scale of the HCV epidemic and the rapidly expanding
formulary of novel therapies undergoing regulatory assess-
ment and re-imbursement decisions worldwide, mean that
this disease area is of great interest in many healthcare
systems [1, 16–19]. Treatment of HCV with pegylated
interferon (PEG) and ribavirin has previously been shown
to be cost–effective, as has triple therapy with PEG, ribavi-
rin and a NS3/4A protease inhibitor [20–21]. However,
uptake of these therapies was low due to their relatively
limited effectiveness, long and complex regimens and
substantial side-effects [22]. This resulted in a contained
budget impact for payers although little advance from the
perspective of patients with HCV. Future treatment op-
tions offer the possibility of all-oral treatment regimens
with good tolerability and excellent efficacy [5–8]. As
many of the previous barriers to HCV treatment have
been comprehensively addressed, cost of treatment will
become one of the most significant. Treatment costs may
be offset by the reduction in the cost of chronic care elic-
ited by successful treatment. However, real-world cost
data for chronic HCV care is sparse internationally and
not previously available in Ireland [16, 23–25]. Submis-
sions to health-technology assessment agencies have been
hampered by the lack of availability of good-quality, up-
to-date cost estimates in this disease area with many of
them utilising costs published in 2006 and established in
Table 2 Summary of patient demographic and healthcare utilisation characteristics in differing HCV health-states
Characteristic Mild Mod. Comp.
Cirrhosis
Decomp.
Cirrhosis
HCC Transplant
Year 1
Transplant >
Year 1
SVR
N 40 29 24 13 27 33 31 28
Mean Age (SD) 38 (8) 48 (10) 45 (9) 46 (7) 55 (11) 47 (9) 54 (9) 34 (10)
Male n (%) 25 (61) 16 (55) 25 (89) 12 (98) 23 (85) 22 (67) 19 (66) 22 (79)
Patient years of follow-up 214 137 102 23 39 33 187 84
Annual mean number of medical
reviews (95%CI)
1.3 (1.1,
1.5)
1.4
(1.2,1.7)
1.8 (1.5, 2.1) 4.6 (4.2, 4.9) 5.2 (4.6,
5.8)
11.9 (10.4,
13.2)
4.3 (4.0, 4.6) 0.36 (0.22,
0.5)
Annual mean number of nursing reviews
(95 % CI)
0.5 (0.3,
0.7)
0.9 (0.6,
1.2)
1.8 (0.9, 2.6) 5.1 (4.3,5.9) 3.6 (3.1,
4.1)
n/a n/a 0.1 (0.0,
0.04)
Annual mean number of inpatient
episodes (95%CI)
n/a n/a 0.2 (0.06,
0.4)
2.5 (2.1, 3.0) 2.1 (1.8,
2.3)
1.1 (0.6, 1.6) 0.24 (0.1, 0.38) n/a
Mod moderate, Comp. cirrhosis Compensated cirrhosis, Decomp. Cirrhosis decompensated cirrhosis, HCC hepatocellular carcinoma, Transplant Year 1 First
12 months of liver transplantation, Transplantation > Year 1 Transplantation After First 12 months, SVR Sustained Viral Response
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2003 [24, 26]. These are likely to be underestimates, par-
ticularly in the high-cost areas of hepatocellular carcinoma
and liver transplantation, as treatment options such as
sorafenib and TACE were not available in 2003 and pre-
scribing practices in post-transplant immunosuppression
have also changed [27]. This study demonstrates that the
direct medical cost associated with HCV care in Ireland is
substantial and that with progression of liver disease the
costs associated with their care increase exponentially. This
is consistent with recent reports from managed care insur-
ance databases in the US, where the cost of HCV care in-
creased substantially with the development of cirrhotic liver
disease [16, 23, 28]. It is estimated that while the incidence
of HCV is falling in many healthcare systems, the peak con-
sumption of healthcare resources is yet to come as increas-
ing numbers of patients with HCV develop complications
of their chronic viral hepatitis [16, 29]. The cost of provid-
ing care to HCV patients will continue to rise unless treat-
ment interventions are initiated to avert disease progression
and avoid high-cost health-states. Given the large propor-
tion of patients who are currently undiagnosed, treatment
strategies aimed at future healthcare cost-containment will
only be successful if patients are identified prior to their
presentation with complications of end-stage liver disease.
The importance of screening as part of this paradigm has
Fig. 1 a Annual Direct Medical Cost of HCV care for milder HCV Health-states (y-axis in €100 s); b Annual Direct Medical Cost of HCV care for advanced
HCV Health-states (y-axis in €10,000 s) OLT =Orthotopic Liver Transplantation, HCC =Hepatocellular Carcinoma, Decomp. = Decompensated, SVR = Sustained
Viral Response
Table 3 Annual mean direct medical costs of chronic HCV care
for patient with different stages of liver disease in Ireland
HCV health-state Mean annual cost (95 % CI)
Mild €398 (€336, €482)
Moderate €417 (€335, €503)
Compensated cirrhosis €1790 (€990, €3164)
Decompensated cirrhosis €8303 (€3945, €14,637)
Hepatocellular carcinoma €21,992 (€15,222, €29,467)
Transplant Year 1 €137,176 (€136,024, €138,306)
Transplant after Year 1 €5337 (€4942, €5799)
Sustained Virological Response €44 (€16, €73)
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been highlighted by recent international recommendations
[3, 30]. The follow-up costs of patients who had achieved
an SVR in this cohort were low in comparison to patients
with ongoing chronic infection and significantly lower than
those for patients with end-stage liver disease.
While the costs associated with advanced liver disease
in HCV are substantial, the vast majority of patients with
HCV at present have mild or moderate disease [23, 31].
The bulk of their management occurs through ambulatory
care and therefore it is appropriate to develop accurate
real-world unit costs of outpatient visits in this setting.
Micro-costing is the recommended method of establishing
unit costs although in practice it is rarely done due to time
constraints [32, 33]. To our knowledge, this study presents
the most detailed breakdown of a HCV routine outpatient
visit. Cost studies have limitations when it comes to gen-
eralising outside of the health care system that they are
derived in, as clinical practice and health care budgets vary
internationally. Nonetheless, the detail provided will allow
others to derive costs by applying unit costs reflective of
their own practice to the resource utilisation of healthcare
personnel and investigations presented, enhancing the
generalisability and relevance of this data to those outside
of Ireland. It provides a “bottom-up” perspective to HCV
care that is lacking from cost estimates derived from large
healthcare insurance databases and comprehensively es-
tablishes ambulatory and pharmacy direct cost estimates
for all disease stages of HCV. The micro-costing study of
ambulatory care was supplemented by DRG costs for in-
patient admissions and procedures in order to give a more
complete description of the cost of advanced HCV dis-
ease. DRG’s have limitations when used in economic
modelling as they may not reflect the true cost of the
admission and may not be representative of costs in other
healthcare jurisdictions as they are derived from an indi-
vidual country’s health care budget [34]. This is particu-
larly relevant in the case of the liver transplantation Year
1 estimate, as the cost of the inpatient liver transplantation
procedure predominates. Research in Ireland and in other
countries has demonstrated that the DRG cost is most
valid in disease areas not undergoing rapid technological
or pharmacological changes [35, 36]. The inpatient man-
agement of advanced liver disease was felt to demonstrate
these features and therefore DRG values were utilised.
The unit DRG cost of liver transplantation, the compo-
nent costs of post-transplant immunosuppression and
prophylaxis and the number of post-transplant ambula-
tory care visits are stated so that international readers can
assess how closely they reflect unit costs and clinical prac-
tice outside of Ireland.
Limitations
This study does not consider costs associated with HCV
treatment. The cost of HCV treatment in Ireland will be
established through the prospectively collected HCV
treatment registry established under the auspices of the
Irish HCV Outcomes and Research Network (ICORN).
This will provide real-world cost estimates of HCV ther-
apy to inform cost-effectiveness and budget impact ana-
lysis in the future. As the study design was retrospective
in nature it is possible that despite efforts to be as pre-
cise as possible with patient categorisation, some of the
patients in the moderate and compensated cirrhosis
groups may have transitioned to more advanced disease
states over the course of the data capture. The numbers
are likely to be small given the slow nature of disease
progression in HCV and the relatively short time frame
considered. Societal costs are not considered in this
study as it concentrates on direct medical costs from the
perspective of the payer. As histological criteria were
used as part of the definition to establish the health-
states that patients were placed in, a relatively large pro-
portion of the cohort had received a liver biopsy. This
may not reflect future practice with the increasing avail-
ability of transient elastometry. Cost studies have limita-
tions when it comes to generalising outside of the health
care system that they are derived in, as described above.
A number of features peculiar to HCV care in Ireland
merit special note: (1) the majority of HCV care in
Ireland is provided by the publicly funded health care
system and therefore these cost estimates may not re-
flect costs in healthcare systems with multiple payers
(2) as treatment for drug dependency in Ireland is
not linked with HCV services in Ireland (other than
one small centre), the cost of drug dependency treat-
ment was not considered, (3) the liver transplantation
service in Ireland is not enrolled in Eurotransplant or
other international organ matching procedures so
costs associated with such procedures are not in-
cluded in the analysis.
Conclusion
HCV is an important public health area that is currently
undergoing a tremendous expansion in therapeutic options
that raise the possibility of effective cure for many patients.
There will be challenges in many healthcare systems in
funding these advances however and cost-effectiveness ana-
lysis will be important to establish the true value and op-
portunity cost associated with them. These detailed real
world cost estimates will be of use to researchers, re-
imbursement decision makers and clinicians alike as they
consider the funding of the new direct acting anti-viral
agents.
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